A detailed history of Thrivent Financial For Lutherans transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Thrivent Financial For Lutherans holds 108,660 shares of DVAX stock, worth $1.24 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
108,660
Previous 153,403 29.17%
Holding current value
$1.24 Million
Previous $1.9 Million 35.92%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$10.73 - $12.58 $480,092 - $562,866
-44,743 Reduced 29.17%
108,660 $1.22 Million
Q1 2024

May 14, 2024

SELL
$11.7 - $14.98 $1.57 Million - $2.01 Million
-134,312 Reduced 46.68%
153,403 $1.9 Million
Q4 2023

Feb 14, 2024

SELL
$13.09 - $14.98 $144,893 - $165,813
-11,069 Reduced 3.7%
287,715 $4.02 Million
Q3 2023

Nov 14, 2023

BUY
$12.64 - $14.99 $44,379 - $52,629
3,511 Added 1.19%
298,784 $4.41 Million
Q2 2023

Aug 14, 2023

SELL
$9.85 - $13.17 $119,726 - $160,081
-12,155 Reduced 3.95%
295,273 $3.82 Million
Q1 2023

May 17, 2023

SELL
$9.44 - $11.88 $274,883 - $345,933
-29,119 Reduced 8.65%
307,428 $3.02 Million
Q4 2022

Feb 08, 2023

BUY
$10.27 - $13.29 $2.21 Million - $2.86 Million
214,961 Added 176.8%
336,547 $3.58 Million
Q3 2022

Nov 14, 2022

BUY
$9.93 - $17.44 $61,327 - $107,709
6,176 Added 5.35%
121,586 $1.27 Million
Q2 2022

Aug 16, 2022

BUY
$7.45 - $12.83 $859,804 - $1.48 Million
115,410 New
115,410 $1.45 Million
Q1 2021

May 17, 2021

SELL
$4.57 - $11.18 $245,358 - $600,243
-53,689 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$3.73 - $5.6 $330,701 - $496,495
-88,660 Reduced 62.28%
53,689 $239,000
Q3 2020

Nov 10, 2020

SELL
$4.32 - $11.7 $2,060 - $5,580
-477 Reduced 0.33%
142,349 $614,000
Q1 2020

May 15, 2020

BUY
$2.27 - $6.2 $324,215 - $885,521
142,826 New
142,826 $504,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.44B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Thrivent Financial For Lutherans Portfolio

Follow Thrivent Financial For Lutherans and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.